Listed by the USPTO as WU, JULIE ZHEN QIN
Tech Center 1600 • Art Units: 1600 1642 1643 1644 1646 1647 1671
This examiner grants 62% of resolved cases
WU, JULIE ZHEN QIN works in tech center 1600 and art unit 1600. The record covers 365 resolved cases, with a 62.5% allowance rate. The median time to allowance is 1200 days, indicating that prosecution outcomes in this docket may require planning for extended examination timelines.
Interviews are associated with a 50.8% lift, making interview preparation a potentially important part of prosecution strategy. The leading companies are The Regents of the University of California, Novartis AG, and Regeneron Pharmaceuticals Inc. The leading firms are BAKER BOTTS L.L.P., MARSHALL, GERSTEIN & BORUN LLP, and NYEMASTER GOODE P.C.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18061221 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | Non-Final OA | Novartis AG |
| 17635054 | CAR-T CELLS SPECIFIC FOR MODIFIED PROTEINS IN EXTRACELLULAR SPACES | Non-Final OA | The Regents of the University of California |
| 17998605 | SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS | Final Rejection | REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17611073 | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER | Final Rejection | Regeneron Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.5% of resolved applications examined by Julie Zhen Qin Wu were allowed (365 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +50.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Julie Zhen Qin Wu took 1,200 days on average from filing to allowance.
Julie Zhen Qin Wu examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
